Paul Tudor Jones's ANIK Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 22,837 shares of Anika Therapeutics, Inc. (ANIK) worth $334,105, representing 0.00% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in ANIK, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2023, adding 36,031 shares. Largest reduction occurred in Q2 2021, reducing 33,185 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Anika Therapeutics (ANIK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Anika Therapeutics (ANIK) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +22,837 | New Buy | 22,837 | $14.63 |
| Q4 2025 | -11,355 | Sold Out | 0 | $0.00 |
| Q3 2025 | +11,355 | New Buy | 11,355 | $9.40 |
| Q2 2025 | -13,628 | Sold Out | 0 | $0.00 |
| Q1 2025 | -22,361 | Reduce 62.13% | 13,628 | $15.03 |
| Q4 2024 | +6,647 | Add 22.65% | 35,989 | $16.46 |
| Q3 2024 | +715 | Add 2.50% | 29,342 | $24.70 |
| Q2 2024 | -7,420 | Reduce 20.58% | 28,627 | $25.33 |
| Q1 2024 | +11,686 | Add 47.97% | 36,047 | $25.40 |
| Q4 2023 | -11,670 | Reduce 32.39% | 24,361 | $22.66 |
| Q3 2023 | +36,031 | New Buy | 36,031 | $18.63 |
| Q2 2021 | -33,185 | Sold Out | 0 | $0.00 |
| Q1 2021 | +15,728 | Add 90.10% | 33,185 | $40.80 |
| Q4 2020 | +5,128 | Add 41.59% | 17,457 | $45.25 |
| Q3 2020 | +12,329 | New Buy | 12,329 | $35.36 |
| Q1 2020 | -30,702 | Sold Out | 0 | $0.00 |
| Q4 2019 | +12,915 | Add 72.61% | 30,702 | $51.85 |
| Q3 2019 | +11,001 | Add 162.11% | 17,787 | $54.87 |
| Q2 2019 | +6,786 | New Buy | 6,786 | $40.67 |
| Q2 2018 | -9,687 | Sold Out | 0 | $0.00 |
| Q1 2018 | -6,604 | Reduce 40.54% | 9,687 | $49.76 |
| Q4 2017 | -2,751 | Reduce 14.45% | 16,291 | $53.89 |
| Q3 2017 | +5,123 | Add 36.81% | 19,042 | $57.98 |
| Q2 2017 | -11,356 | Reduce 44.93% | 13,919 | $49.36 |
| Q1 2017 | +8,206 | Add 48.08% | 25,275 | $43.44 |
| Q4 2016 | +4,238 | Add 33.03% | 17,069 | $48.98 |
| Q3 2016 | +12,831 | New Buy | 12,831 | $47.85 |
| Q2 2016 | -4,911 | Sold Out | 0 | $0.00 |
| Q1 2016 | +4,911 | New Buy | 4,911 | $44.80 |
| Q3 2014 | -6,759 | Sold Out | 0 | $0.00 |
| Q2 2014 | -3,894 | Reduce 36.55% | 6,759 | $46.31 |
| Q1 2014 | +10,653 | New Buy | 10,653 | $41.12 |
Paul Tudor Jones's Anika Therapeutics Investment FAQs
Paul Tudor Jones first purchased Anika Therapeutics, Inc. (ANIK) in Q1 2014, acquiring 10,653 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Anika Therapeutics, Inc. (ANIK) for 32 quarters since Q1 2014.
Paul Tudor Jones's largest addition to Anika Therapeutics, Inc. (ANIK) was in Q3 2023, adding 36,031 shares worth $671,258.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 22,837 shares of Anika Therapeutics, Inc. (ANIK), valued at approximately $334,105.
As of the Q2 2026 filing, Anika Therapeutics, Inc. (ANIK) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Anika Therapeutics, Inc. (ANIK) was 36,047 shares, as reported at the end of Q1 2024.